Global Mice Model Market Overview
The global mice model market is expected to grow at a strong ~9% CAGR over the next five years, fueled by increasing demand for personalized medicine, broader use in preclinical research, rising burden of chronic and infectious diseases, rapid advancements in genetic engineering technologies, and robust funding for biomedical research.
Mice models have become essential in modern research due to their genetic, biological, and behavioral similarities to humans. They are widely used to study disease mechanisms at the molecular level, assess drug safety and efficacy, understand gene functions, and support the development of targeted therapies.
Key Request a free sample copy or view report summary: https://meditechinsights.com/mice-model-market/request-sample/
A mice model refers to a laboratory mouse used to analyze human disease processes, gene activity, and treatment responses. These models include naturally occurring strains, genetically modified variants such as knockout and transgenic mice, and humanized models carrying human genes or tissues. Their high predictive accuracy makes them critical in drug discovery, toxicology, immunology, regenerative medicine, and precision healthcare.
Increasing Demand for Personalized Medicine
The rising global focus on personalized and precision medicine has become a major catalyst for the mice model market.
As healthcare moves toward tailored treatments based on individual genetics, researchers need models that mimic human biological responses with high accuracy.
Genetically engineered models, including humanized mice, allow scientists to study unique patient-specific genetic variations.
These models facilitate biomarker discovery and help measure how different genotypes respond to specific molecules.
Pharmaceutical and biotechnology industries increasingly depend on advanced mice models to optimize preclinical experiments.
Personalized models improve translational outcomes, helping reduce failures in clinical trials and speed up therapy development.
Growth in genomics, next-generation sequencing, and diagnostic insights further drives the expansion of precision-based mouse studies.
Advancements in Gene-Editing Technologies
Gene-editing breakthroughs, especially CRISPR/Cas9, are redefining the mice model landscape.
CRISPR enables rapid creation of knockout and knock-in mice, reducing timelines from years to months.
These models provide exceptionally accurate mimicry of human genetic disorders.
CRISPR-engineered humanized mice support oncology, immunology, neurology, and metabolic disease research.
Multiplex editing allows simultaneous alteration of multiple genes, enabling analysis of gene interactions and complex disorders.
Lower production costs and increased editing precision have further accelerated adoption.
CRISPR-driven advancements are enhancing functional genomics, pathway analysis, and targeted drug development using mice models.
Competitive Landscape Analysis
The global mice model market features a mix of established companies and emerging biotechnology innovators.
Key players include Charles River Laboratories, The Jackson Laboratory, Inotiv, genOway, Cyagen, Janvier Labs, Shanghai Model Organisms Center, Harbour BioMed, GemPharmatech, and Hera Biolabs.
Leading companies focus on expanding customized model offerings, developing advanced genetic engineering services, and creating highly specialized humanized mice platforms.
Strategic partnerships between research institutes, CROs, and biotech firms enhance access to technology and expand market reach.
Geographic expansion, facility upgrades, and investment in next-generation breeding and genetic facilities are common growth strategies.
Innovation-driven collaborations and co-development agreements continue to shape the competitive dynamics of the market.
Market Drivers
- Growing demand for personalized medicine
- Expanding applications in preclinical research
- Increasing prevalence of chronic and infectious diseases
- Continuous advancements in genetic engineering technologies
- Strong investments in biomedical research
The rising incidence of diseases such as cancer, diabetes, cardiovascular disorders, autoimmune conditions, and viral infections is accelerating the need for advanced disease models. Pharmaceutical companies are increasingly relying on mice models for early-stage testing, safety assessment, and therapeutic validation. Meanwhile, innovations in gene-editing technologies are boosting the adoption of genetically engineered and humanized models. Significant funding from governments and private organizations is further strengthening the research ecosystem.
Attractive Market Opportunities
- Increasing use in oncology and immunology research
- Growing adoption of humanized mice models
- Expanding role of contract research organizations (CROs)
- Rising demand across emerging markets
Oncology remains the leading application area due to the global cancer burden. Humanized mice models are gaining traction for immuno-oncology, CAR-T therapy research, vaccine development, and infectious disease studies. CROs are contributing significantly by offering scalable and cost-effective research services using advanced models. Additionally, emerging regions such as Asia, Latin America, and the Middle East are witnessing rapid growth in biomedical research infrastructure, creating new opportunities.
Conclusion
The global mice model market is set for sustained growth, driven by technological advancements, increasing focus on personalized medicine, and expanding understanding of disease biology. Innovations such as CRISPR-based gene editing, the rising availability of humanized models, and the growing role of CROs are enhancing market potential. With increasing research investments and wider application areas, the market presents significant opportunities for stakeholders across the healthcare and life sciences ecosystem.
Download pdf Brochure: https://meditechinsights.com/mice-model-market/request-sample/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
